Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
On the contrary my understanding is that generics can legally swing a certain percentage in either direction - I think its 25 % - therefore you could have up to a 50 % variation if effectiveness - with medications such as coumadin thyroid replacement insulins etc this can be a major issue
KO in first round .... all other challengers throw in the towel ....
Welcome to Vastor ... the statin ENHANCER ... Doctor would you like to reduce your patients cardiac events by 25% on top of what a statin already does ?
YOu can - by simply prescribing Vastor as your statin . Vastor harnesses up the proven benefit of statins but also adds a statin enhancer giving an additional 25% reduction of cardiac events
AMRN should have gone after this long ago -
1.) go after the entire statin market -
2.) Its not fish oil its a statin enhancer
3.) Combo prevents infringement
4.) Docs understand statins - the term statin enhancer lets their mind ride on the statin term so easy to sell
. any substitution is obvious infringement ... one way or the other .. either by law suits or the reset button ... if insurance now say to he doc no you must wirter two rx one fro gV and for the statin then they are inducing infirnegment
He will be glad to post them ....in 12 months
That would be difficult because Predicting the past is not an accurate science ....
This is going to be fascinating. AS I recall the ADCOM for this drug was substantially against approval
Today, the U.S. Food and Drug Administration (FDA) Peripheral and Central Nervous System Drugs Advisory Committee voted 1 yes, 8 no and 2 uncertain on the question, “Does Study 302 (EMERGE), viewed independently and without regard for Study 301 (ENGAGE), provide strong evidence that supports the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”.
The Advisory Committee also voted 0 yes, 7 no and 4 uncertain on the question, “Does Study 103 (PRIME) provide supportive evidence of the effectiveness of aducanumab for the treatment of Alzheimer’s disease?”, and
5 yes, 0 no and 6 uncertain on the question, “Has the Applicant presented strong evidence of a pharmacodynamic effect of aducanumab on Alzheimer’s disease pathophysiology?”.
Finally, the Advisory Committee voted 0 yes, 10 no and 1 uncertain on the question, “In light of the understanding provided by the exploratory analyses of Study 301 and Study 302, along with the results of Study 103 and evidence of a pharmacodynamic effect on Alzheimer’s disease pathophysiology, it is reasonable to consider Study 302 as primary evidence of effectiveness of aducanumab for the treatment of Alzheimer’s disease?”
WHo is behind the patent attacks in EU ?
Would have to agree - a flawed character that obfuscates the facts in an attempt to cover up his mistakes - perhaps being financed by BP - he is unable to accept that he misunderstood the basic biochemistry of Omega 3's - but so far I would have to say I misunderstood AMRN and all of the forces that exist outside of the science for biopharmaceutical firms - but thats why companies have CEO's lawyers and other business professionals too bad AMRN's were getting on the job training which cost billions while milking the company for millions
Yes this conundrum of a quagmire known as vascepa ..... would enjoy others inputs on this - possible reasons ....
1.) AMRN is asking too much
2.) THey believe STevie and its 'all in the placebo'
3.) They intend to pick up the company but are waiting to drive the price lower ( IF thats the case they should be buying now at 100% premium or $6 per share)
4.) Pfizer believes its new product to be much more effective ( but again why not start now with vascepa and transition into it - studies are going to take prob 4 - 5 years )
5.) Let AMRN pay to build the concept of residual lipid risk and then step into already built market
6.) No one is aware of the med and the potential ( AMRN's fault)
7.) No one willing to fight infringement - or waiting for infringement issue to be resolved
For WHom the Bell TOlls ....
PFIZERs new drug - in the wings phase 2 injectable not proven ...and they see more value in this than buying AMRN ......
I would have to agree ... Thero and Cronies should be made to pay back the millions they looted from the company
Yes so then why would PFizer go ahead and invest in a new drug that is not proven in Phase 2 studies - when they have a proven winner waiting to be bought out ....
Reminds me of government workers - we need line inspectors for the roads - Believe it or not these are actual paid positions in NY - after all if you have been painting lines on the road for 20 years you might not know how to do it but wait a minute the line inspectors might not do their work so we need inspectors of inspectors ...and then inspectors of inspectors of inspectors .... and then at some point the peasants revolt
IF HIKMA knew that the would be able to continue to infringe without limitation there would be no need for this new suit. The fact that they have brought his new suit tells me that they are uncertain
So I guess for the FDA and all the experts they hired - it was nOT so obvious - which is why they required REDUCE IT study - this si nothing short of hilarious - it was obvious - thats why the FDA required a study
LM - does the fact that AMRN has refused to take action for shareholders by default give shareholders standing ? It seems to me that shareholders should be able to respond to an issue that the BOD has missed? The company has failed the shareholders - shareholders then step forward
Seems if shareholders are refused standing the next step is then to take AIM at AMRN for failing to address the issue ?
Leerink Partners analyst Roanna Ruiz maintained a Buy rating on Amarin (NASDAQ:AMRN) Corporation Plc on Monday, setting a price target of $12, which is approximately 233.33% above the present share price of $3.6.
Ruiz expects Amarin Corporation Plc to post earnings per share (EPS) of -$0.03 for the fourth quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in Amarin, with an average price target of $8.25.
The analysts price targets range from a high of $12 to a low of $4.5.
I have found cologuard to be a pain in the butt ...no pun intended
90% of the findings are false + - then the patient needs colonoscopy currently and in 3 years! - its actually increasing testing rather than decreasing it
I have 8 Insurance denials for Vascepa sitting in my inbox right now -
I believe a lot of the downward pressure is because of Pfizers / IONIS new drug that is clearly seeking to replace Vascepa and we dont have an answer why PFIZER would not seek to buy AMRN
The new med is an injection - its probably going to cost a fortune it has not yet been proven to reduce cardiac events will have more side effects than Vascepa -
WHy run down that trail full of unknowns when a clear path sits in front of you ? Doesnt make sense to me ...
Until I can understand why PFIZER is going in this direction I will be very hesitant to look for any significant escalation in stock price ...
Thanks Marjac !
From a non legal perspective I found the following definitions of interest
JUdge Du says AMRN has standing yet tries to say shareholders dont
So the employees of AMRN can bring a suit yet stockholders cant
SHe has redefined shareholders as not being stakeholders - this is a blatant falsehood
Many people have a vested interest in the success of a company. If you own a portion of it, you want it to succeed because then you get a cut of the profits. These individuals are defined as “shareholders.”
If you have a financial interest in the company other than ownership, say you work for it, you still want it to succeed. Everyone who wants the corporation to succeed is called a “stakeholder.”
Not every stakeholder is a shareholder but every shareholder is a stakeholder - except in JUdge Du's world.
If its #2 It is my opinion Judge DU does not have the character to admit her mistake and although she would recognize the cropped table she would still rule against AMRN ( ie "see I was right all along " )
Yes but they will have to lay out millions in research the research may fail etc and there sits VASCEPA - complete with FDA approval scientific evidence etc - so why wont they buy it - to me this is a huge red flag ?
Possibilities :
1.) They believe their product will be more effective
2.) They do intend to buy AMRN start with VASCEPA build the market for residual risk and then transition to their new product if the research is successful
3.) They buy into Stevie's kool aid and expect future studies with minerla oil to prove REDUCE IT wrong
4.) Cost to purchase AMRN is well beyond the risk they wish to take vs developing a new product
Its an injection - its probably going to cost a fortune it has not yet been proven to reduce cardiac events will have more side effects than Vascepa -
OK someone explain to me why they are pursuing this vs not just making VASTOR ???
NIce slide FFS !
One would have to question why a pharmaceutical firm would want to out lay the significant financial resources necessary to perform these studies with no guarantee of success vs just buying an established product with a proven study ?
Exactly I am interested in profit - loss thats it - everybody is an expert - ironic how all these experts wont actual tell you when they buy or sell - its all rather entertaining
Because the proof is in the pudding ....the only thing that matters is did you make money
Yes my last purchase is down 9% - the question is why do you cite that if you are not interested in actual profit or loss but the why ?
Please give evidence of buy and sell actions which are not retrospective in nature - I value opinions on both sides of the equation and therefore welcome yours - what I dont value stating they predicted something that is not verifiable by theri buy or sell actions
I have clearly stated when I buy and when I sell
Great ... another buying opportunity !!!
$2.77 wow great buying opportunity ...cant wait !!
Ozempic will now be strongly marketing their CVD benefits for diabetics ....
Vascepa
NRx (+456)
Generic Vascepa
NRx (+425)
ok 425 does not equal 456 .... but thats not the point
the point is NEW gV Rx's are nearly = to V
I find that disconcerting
gV now = V - this is direct evidence of infringement imho - since 90% of V's market is CAD - how can any thinking judge not view this as infringement is beyond me ....
You know I dont consider myself any form of financial expert but Id like to form a Capital Acquisition COrporation - People give me money to invest I then have an IPO and sell share at $10 but give myself a bunch at $0.005 - sell them off later at near $10 how do you lose at that game ???? Reminds me of JT and crew at AMRN
On August 13, 2020, we issued to our sponsor 5,031,250 founder shares in exchange for a capital contribution of $25,000, or approximately $0.005 per share.
17,500,000 units (or 20,125,000 units if the underwriters’ over-allotment option is exercised in full), at $10.00 per unit, each unit consisting of:
Couldn't agree more ..maybe we can borrow that big red reset button ...
There needs to be a mutifaceted approach to the US
1.) Not one more mention of fish oil
2.) Educate DOcs regarding the distinct difference between dha and epa
3.) Educate Insurers
4.) Educate the public
5.) Launch advertising campaign indicating that if you are not receiving vascepa and have known heart disease your risk of having an event just increased by 25%
I cant emphasize enough how advertising that one sentence would effect Rx numbers !
6.) Institute many more legal actions against insurers / PBM's that allow infringement
7.) They need articles in primary care journals ( Pharmacy Dude if you want to writhe one with me for American Family Physician let me know ).
the list goes on and on
Its not doing much as a stock ....
https://www.google.com/finance/quote/SRSA:NASDAQ?window=5Y
Fascinating IRONWOOD a one product company appointed DEnner ( Dr. Denner is the founding partner and chief investment officer of Sarissa Capital Management LP) to its BOD ....
https://investor.ironwoodpharma.com/press-releases/press-release-details/2020/Ironwood-Pharmaceuticals-Appoints-Alexander-Denner-Ph.D.-to-Board-of-Directors/default.aspx
dont know if anyone posted this
https://www.medscape.com/viewarticle/962972